跳至主要内容
临床试验/NCT02678481
NCT02678481Unknown不适用

MR-targeted vs. Random TRUS-guided Prostate Biopsy in Patients With High PSA Values and Previous Negative Biopsy Results: A Randomized Controlled Trial

Fondazione del Piemonte per l'Oncologia2 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2014年11月最近更新:
适应症

试验速览

阶段
不适用
入组人数
90
试验地点
2
主要终点
Prostate cancer detection rate

研究概览

简要总结

To compare prostate cancer (PCa) detection rate of magnetic resonance (MR)-targeted biopsy and transrectal ultrasound (TRUS)-guided biopsy in patients with high PSA values and at least one previous negative prostate biopsy. Subjects will be submitted to a multiparametric MR scan of the prostate and subsequently patients with a suspicious MR for PCa presence will be randomized (1:1) into the two study arms.

详细描述

In men with previously negative prostate biopsy and persistent elevated PSA value, it is unclear which biopsy strategy offers the highest detection rate for significant PCa. The hypothesis of this study is that MR-targeted biopsy improves the detection rates of significant prostate cancers compared with systematic TRUS-guided prostate biopsy.

Men with at least one previously negative TRUS-guided biopsy and persistently elevated PSA values (> 4 ng/ml) will be submitted to a multiparametric MR imaging examination of the prostate. Subsequently, participants with suspected regions at MR imaging will be randomized (1:1) into the two study arms. In study arm A patients will be submitted to MR-targeted in-bore prostate biopsy based on the multiparametric MR imaging findings. In study arm B patients will be submitted to systematic TRUS-guided prostate biopsy with saturation scheme.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
50 Years 至 80 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • men aged 50-80
  • at least one negative TRUS-guided prostate biopsy
  • PSA > 4 ng/ml
  • at least one suspected region detected at multiparametric MR imaging
  • signed informed consent

排除标准

  • known prostate cancer diagnosis
  • contraindication against MR imaging or uncooperative patients

结局指标

主要结局

Prostate cancer detection rate

时间窗: within the 3 months after MR imaging

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验